Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

e rapid onset of action."

"Reaching the patient enrollment target in our Phase III clinical trial of Omigard for the prevention of catheter-related infections is a major milestone in our clinical development program for this product candidate," stated James Breitmeyer, M.D., Ph.D., Executive Vice President, Development and Chief Medical Officer of Cadence. "If approved, we believe that Omigard will address a rapidly growing need for more effective ways to lower hospital acquired infection rates, including the dangerous and costly complications from infections related to intravascular catheters."

Cadence's second clinical trial of Acetavance for the treatment of fever in adults, designated Study 303, was a Phase III, randomized, double-blind, double-dummy, single-dose study of intravenous acetaminophen (1 gram) compared to oral acetaminophen (1 gram) for the treatment of fever in 81 adult volunteers with experimentally-induced fever. In this study, a statistically significant difference in favor of Acetavance was observed compared to oral acetaminophen for the primary efficacy endpoint of WSTD2 (the weighted sum of temperature differences over two hours) (p< 0.01). The mean temperature scores for patients in the Acetavance-treated group were significantly lower as early as 15 minutes after the study drug was administered. The peak temperature observed in the Acetavance group of patients was also significantly lower. Acetavance was very well tolerated, including no treatment-emergent serious adverse events or treatment-emergent hepatic adverse events.

Cadence's confirmatory Phase III clinical trial of Omigard (omiganan pentahydrochloride 1% gel), known as the Central Line Infection Reduction Study, or CLIRS, is a randomized, evaluator-blinded study in hospitalized patients whose medical condition requires a short-term central venous catheter. The primary objective of CLIRS is to evaluate the efficacy and safety of Omigard compared to 10% povidone-
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DALLAS , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Crystallography Scanner Industry, 2009-2019 is a professional and ... X-Ray Crystallography Scanner industry . The report firstly ... including its classification, application and manufacturing technology. The ... of X-Ray Crystallography Scanner listing their product specification, ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products ... for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it has ... address a potential issue with a clip used ... Axilla application of the SAM Junctional Tourniquet (SJT).  ...
(Date:8/29/2014)... PARK, Calif. , Aug. 29, 2014 ... Medical as CEO and member of the Board of ... decades of medical device development and commercialization experience, including ... field. Mr. Engelson previously served as a Partner of ... as President and CEO of two Foundry start-ups. Mr. ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2
... of RedChip Companies to Lead Public and Investor Relations Efforts -- BEIJING, Sept. 8 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are ...
... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP ... care, today announced that the Company will present at the ... on Tuesday, September 14th at 9:35AM ET in the Fahnestock ... Palace Hotel.   On Tuesday, Jeffrey Davis, Chief ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts 2Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts 3Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts 4Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts 5Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts 6Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts 7Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts 8Access Pharmaceuticals to Present At Rodman & Renshaw Annual Global Investment Conference in New York City 2Access Pharmaceuticals to Present At Rodman & Renshaw Annual Global Investment Conference in New York City 3
(Date:9/2/2014)... Falls, New York (PRWEB) September 02, 2014 ... ?” This is the question that millions of people ... among health care providers, patients and their families or ... to misdiagnosis due to its distinct similarities to other ... dermatitis, impetigo, bed bug bites, eczema, varicella and many ...
(Date:9/2/2014)... September 02, 2014 Michigan’s health care ... Care Act and the Healthy Michigan Plan. Throughout these ... remains a trusted funding resource for under-served individuals. Federal ... uninsured or underinsured women between the ages of 50 ... 250 percent of the federal poverty level. ...
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides ... collection of employee internet monitoring products ( http://www.os-monitor.com ). ... up to 10% off, on these useful items. ... than 20 different kinds of high end monitoring programs ... for companies of all sizes. With its high end ...
(Date:9/2/2014)... Barcelona, Spain Tuesday 2 September 2014: A simple ... atrial fibrillation (AF), according to research presented at ESC ... Professor Davy said: "Atrial fibrillation (AF) is the most ... failure risk by three-fold and the risk of stroke ... stroke in 1 of 4 cases. However, AF is ...
(Date:9/2/2014)... California (PRWEB) September 02, 2014 Developers ... have announced a new ProIntro Lesson from Pixel Film ... create easy and fresh-looking titles,” said Christina Austin, CEO ... and armature, ProIntro is a definite game changer.” , ... the ProIntro Lesson from Pixel Film Studios. ProIntro is ...
Breaking Medicine News(10 mins):Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3
... been sent to people traveling to the Indian Ocean. ... bites.// ,93 cases have been reported by ... last year’s average of 6. ,According to the HPA's ... had cases of mosquito-borne virus.,Insect repellents, long trousers and ...
... of the awareness of obesity epidemic afflicting the kids in ... of these actions is not up to the mark. ... Progress in Preventing Childhood Obesity: How Do We Measure Up?, ... ,"The very health of the country hangs in ...
... “crisis” over lack of donors at sperm bank clinics. According to ... stock//, women and couples wanting to have children were facing a ... was 459. Ever since, the number had been decreasing. To make ... kids the right to know the identity of their donor father ...
... start by next week the distribution of a drug to ... ,South Africa is being affected by an extremely virulent ... 52 people in the country. The health officials have now ... early as next week to help fight the disease. The ...
... US is asking for an extensive study for the evaluation ... the use of stents. // ,Stents are widely ... eluting stents are had essentially eliminated short-term restenosis as a ... come under a cloud for possible late-term risks. Reports indicate ...
... In a unique way to curb binge drinking, researchers say parents ... that allowing youngsters // to drink at parties and at home ... ,Professor Mark Bellis, the author of the report said ... in moderation and allowed to drink with them were sensible in ...
Cached Medicine News:Health News:Slow Fight Against Childhood Obesity 2Health News:Slow Fight Against Childhood Obesity 3Health News:Shortage of donors at sperm bank clinics 2Health News:South Africa To Make Available Two New Drugs To Fight The TB Outbreak 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: